Podcast Episodes
Back to Search
Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More
Novartis started the week early with a Sunday afternoon announcement of the acquisition of neuromuscular drug developer Avidity Biosciences for $12B.…
8 months, 1 week ago
How Supply Chain Turbulence is Reshaping Biotech Strategy
In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney how in light of economic uncertainty, small biotechs can turn to inter…
8 months, 2 weeks ago
Novo Board Upended, ESMO Excitement, FDA Awards, Replimune’s U-Turn
Novo Nordisk dominated the news cycle this week, with more leadership changes as the Novo Foundation replaced the company’s board, which will now be …
8 months, 2 weeks ago
Cost Control to Capability Building: Rethinking Supply and Strategy in Pharma
In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney will explore how healthcare and pharmaceutical players — from hospital…
8 months, 2 weeks ago
Work Smart, Build Trust: Connecting Technology, Patient Compliance and Data Processing
This episode continues the discussion with Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII, as …
8 months, 3 weeks ago
Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC
Johnson & Johnson kicked off Q3 earnings season on Tuesday with the announcement that it is splitting its orthopedics and medtech operations and that…
8 months, 3 weeks ago
Bonus: Q3 2025 Job Market Update
In this discussion, BioSpace’s vice president of marketing Chantal Dresner and careers editor Angela Gabriel take a look at job market perfor…
8 months, 3 weeks ago
Shutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa
The U.S. government is now in its second week of a shutdown—with the FDA having paused acceptance of all new drug applications for the duration. But …
9 months ago
Hit Me With Your Best Shot: Understanding Autoinjectors and Combination Drug Delivery Systems
Clinical trials can present many challenges for patients–particularly injections.
Oliver Eden, senior business unit director at Jabil, and Travis Webb…
9 months, 1 week ago
M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s
Genmab closed out a busy third quarter for M&A in biopharma, picking up cancer biotech Merus for $8 billion. This deal—the year’s fifth largest—came …
9 months, 1 week ago